PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2020 | 10 | 1 | 5-7
Article title

Transcatheter aortic valve replacement in a patient with renal cell carcinoma. A case report

Content
Title variants
Languages of publication
EN
Abstracts
EN
The transcatheter aortic valve replacement (TAVR) is an important therapy for symptomatic patients with severe aortic stenosis who have an intermediate or high surgical risk. The profile of patients eligible for this therapy as first choice has changed over the last few years, with increasing indication even for patients who do not have surgical high risk. Severely ill and frail patients, elderly or patients with multiple clinical comorbidities, such as cancer might be considered for TAVR.
Discipline
Publisher

Journal
Year
Volume
10
Issue
1
Pages
5-7
Physical description
Contributors
  • Department of Cardio-Oncology of the Cancer Institute of Sao Paulo, University of Sao Paulo
  • Department of Cardio-Oncology of the Cancer Institute of Sao Paulo, University of Sao Paulo
  • Department of Cardio-Oncology of the Cancer Institute of Sao Paulo, University of Sao Paulo
  • Department of Cardio-Oncology of the Cancer Institute of Sao Paulo, University of Sao Paulo
  • Heart Institute of Sao Paulo, University of Sao Paulo
  • Heart Institute of Sao Paulo, University of Sao Paulo
  • 1. Department of Cardio-Oncology of the Cancer Institute of Sao Paulo, University of Sao Paulo. 2. Heart Institute of Sao Paulo, University of Sao Paulo
References
  • 1. Schechter M, Balanescu DV, Donisan T et al. An update on the management and outcomes of cancer patients with severe aortic stenosis. Catheter Cardiovasc Interv. 2019; 94(3): 438-45.
  • 2. Schofer N. Transcatheter Aortic Valve Replacement in Oncology Patients: Does it Make Sense? JACC Cardiovasc Interv. 2019; 12(1): 87-9.
  • 3. Berkovitch A, Guetta V, Barbash IM et al. Favorable Short-Term and Long-Term Outcomes Among Patients With Prior History of Malignancy Undergoing Transcatheter Aortic Valve Implantation. J Invasive Cardiol. 2018; 30(3): 105-9.
  • 4. Baumgartner H, Falk V, Bax JJ et al; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38(36): 2739-91.
  • 5. Mack MJ, Leon MB, Thourani VH et al; PARTNER 3 Investigators. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low- -Risk Patients. N Engl J Med. 2019; 380(18): 1695-705.
  • 6. Watanabe Y, Kozuma K, Hioki H et al. Comparison of Results of Transcatheter Aortic Valve Implantation in Patients With Versus Without Active Cancer. Am J Cardiol. 2016; 118(4): 572-7.
  • 7. Landes U, Iakobishvili Z, Vronsky D et al. Transcatheter Aortic Valve Replacement in Oncology Patients With Severe Aortic Stenosis. JACC Cardiovasc Interv. 2019; 12(1): 78-86.
  • 8. Mangner N, Woitek FJ, Haussig S et al. Impact of active cancer disease on the outcome of patients undergoing transcatheter aortic valve replacement. J Interv Cardiol. 2018; 31(2): 188-96.
  • 9. Reardon MJ, Van Mieghem NM, Popma JJ et al; SURTAVI Investigators. Surgical or Transcatheter Aortic Valve Replacement in Intermediate Risk Patients. N Engl J Med. 2017; 376(14): 1321-31.
  • 10. Bourantas CV, Serruys PW. Evolution of transcatheter aortic valve replacement. Circ Res. 2014; 114(6): 1037-51.
  • 11. Nishimura RA, Otto CM, Bonow RO et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017; 70(2): 252-89.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-17ca7be4-1501-4c11-87b7-e51a5f08ecf4
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.